Saturday 17 October 2026
Export RARE’s income statement to Excel — free account
Ultragenyx Pharmaceutical Inc.
RARE Healthcare Biotechnology
Ultragenyx Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $673.0 million, up 20.2% from fiscal 2024. In the quarter to June 2026, revenue grew 28.1%, EPS grew 23.1% and free cash flow grew 12.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
14.54
0.63
−4.15%
Follow RARE
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
5 | 4 | 4 | 3 | 3 | 5 | 4 | 4 | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
3.37 | 6.80 | 8.16 | 8.76 | 16.22 | 31.08 | 23.30 | 42.03 | 767.05 | 0.00 |
Altman Z-Score |
(3.57) | (2.28) | (2.05) | (1.56) | 3.73 | 7.35 | 0.89 | 8.85 | 6.91 | 22.93 |
Altman Z″-Score (non-manufacturers) |
(9.61) | (8.70) | (7.75) | (5.73) | (1.60) | 1.86 | (0.88) | 1.72 | (3.63) | 5.33 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
(22.72) | (48.00) | (42.10) | (35.23) | (104.91) | (134.87) | (33.54) | (38.75) | (25.57) | (58.09) |
Beneish M-Score |
(2.68) | (2.55) | (2.08) | (3.27) | (2.38) | (1.91) | (0.53) | 14.07 | — | — |
P/B ratio |
0.00 | 14.93 | 12.86 | 9.03 | 6.18 | 7.30 | 3.70 | 3.55 | 5.46 | 5.84 |
Price to Tangible BV |
0.00 | 115.37 | 54.69 | 21.51 | 7.63 | 8.60 | 5.03 | 4.97 | 10.59 | 5.84 |
EV/Sales |
2.36 | 5.71 | 6.83 | 6.70 | 14.12 | 26.64 | 16.02 | 33.10 | 681.09 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(3.41) | (7.72) | (6.24) | (6.40) | (14.65) | (54.62) | (4.81) | (5.87) | (7.32) | (14.84) |
EV/FCF |
(3.26) | (7.37) | (5.68) | (4.62) | (12.05) | (41.00) | (4.49) | (5.78) | (7.24) | (13.95) |
Quick Ratio |
2.18 | 2.13 | 2.32 | 3.02 | 4.24 | 6.46 | 7.63 | 6.32 | 3.37 | 6.33 |
Current Ratio |
2.48 | 2.38 | 2.61 | 3.38 | 4.72 | 6.83 | 8.24 | 6.99 | 3.80 | 6.67 |
Net Debt/EBITDA |
1.35 | 1.19 | 1.04 | 1.19 | 2.05 | 3.79 | 1.79 | 1.30 | 0.73 | 1.59 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.44 | 0.37 | 0.29 | 0.24 | 0.21 | 0.19 | 0.11 | 0.09 | 0.01 | 0.00 |
Operating CF/Net income |
0.81 | 0.73 | 0.78 | 0.54 | 0.75 | 0.71 | 0.86 | 1.47 | 0.84 | 0.65 |
Capex/Depreciation |
(0.68) | (0.87) | (3.62) | (6.99) | (3.68) | (3.35) | (10.68) | (0.24) | (0.37) | (1.23) |
Interest Coverage |
(8.63) | (8.51) | (8.62) | (15.09) | (12.97) | (9.92) | (373.72) | (38.92) | (80.74) | (65.45) |
| (657.14%) | (214.55%) | (193.34%) | (110.96%) | (43.72%) | (20.64%) | (63.79%) | (39.83%) | (70.48%) | (48.93%) | |
| (37.89%) | (38.01%) | (39.98%) | (46.12%) | (27.67%) | (12.89%) | (43.42%) | (32.65%) | (58.59%) | (44.70%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | (130.83%) | 0.00% | 0.00% | (155.57%) | (138.02%) | (167.73%) |
Return on Tangible Assets |
(70.90%) | (77.00%) | (81.77%) | (80.17%) | (55.61%) | (15.82%) | (50.85%) | (42.25%) | (137.08%) | (68.59%) |
Average Days of Receivables |
85.69 | 79.52 | 61.72 | 40.63 | 29.53 | 31.10 | 115.59 | 90.30 | 722.73 | 0.00 |
Research and Development Expense of Revenue |
111.44% | 124.64% | 149.31% | 194.26% | 141.48% | 152.04% | 344.56% | 570.93% | 8,868.45% | 137,747.37% |
Selling, General and Administrative Expense of Revenue |
51.86% | 57.32% | 71.43% | 76.55% | 62.60% | 67.50% | 155.74% | 248.03% | 3,825.00% | 48,824.06% |
Intangible Assets out of Total Assets |
0.14 | 0.15 | 0.14 | 0.13 | 0.12 | 0.10 | 0.15 | 0.24 | 0.38 | 0.00 |
Share Based Compensation of Revenue |
22.73% | 28.21% | 31.11% | 35.88% | 29.87% | 31.63% | 79.06% | 155.56% | 2,603.91% | 36,322.56% |
Graham Net Nets |
(0.29) | (0.11) | (0.14) | (0.10) | 0.05 | 0.08 | 0.15 | 0.19 | 0.08 | 0.12 |
Graham Number |
10.33 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(25.39%) | (15.07%) | (17.29%) | (22.21%) | (7.98%) | (2.26%) | (16.67%) | (8.97%) | (14.42%) | (8.86%) |
Free Cash Flow Yield |
(21.47%) | (11.40%) | (14.74%) | (16.55%) | (7.22%) | (2.09%) | (15.32%) | (13.61%) | (12.26%) | (6.18%) |
Revenue per Share |
6.83 | 6.19 | 5.90 | 5.20 | 5.18 | 4.45 | 1.83 | 1.03 | 0.06 | 0.00 |
Operating CF per Share |
(4.73) | (4.57) | (6.46) | (5.44) | (5.00) | (2.17) | (6.10) | (5.84) | (5.98) | (4.07) |
Capex per Share |
(0.21) | (0.22) | (0.64) | (2.09) | (1.08) | (0.72) | (0.44) | (0.08) | (0.07) | (0.26) |
Free Cash Flow per Share |
(4.94) | (4.80) | (7.10) | (7.53) | (6.07) | (2.89) | (6.54) | (5.92) | (6.05) | (4.32) |
Cash per Share |
6.90 | 6.74 | 7.85 | 10.70 | 10.92 | 19.75 | 13.35 | 9.24 | 5.52 | 9.64 |
Shareholders Equity per Share |
(0.81) | 2.82 | 3.75 | 5.04 | 13.61 | 18.97 | 11.56 | 12.23 | 9.03 | 11.97 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.81) | 2.82 | 3.75 | 5.04 | 13.61 | 18.97 | 11.56 | 12.23 | 9.03 | 11.97 |
Free Cash Flow |
(487.00) | (434.00) | (522.00) | (526.59) | (411.79) | (176.12) | (370.21) | (294.64) | (256.64) | (171.16) |
Working Capital |
567.00 | 473.00 | 451.75 | 622.69 | 675.24 | 1,105.70 | 747.72 | 447.64 | 198.57 | 341.44 |
Capital Expenditures |
(21.00) | (20.00) | (47.00) | (146.12) | (73.09) | (43.90) | (24.83) | (4.08) | (2.79) | (10.19) |
Net Current Asset Value |
(661.00) | (431.00) | (483.41) | (309.05) | 256.77 | 690.12 | 369.29 | 411.72 | 162.28 | 335.04 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.03 | 0.04 | 0.11 | 0.40 | 0.21 | 0.16 | 0.24 | 0.08 | 1.07 | 76.60 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.13 | 0.09 | 0.04 | 0.08 | 0.14 | 0.18 | 0.05 | 0.84 | 0.34 | 0.48 |
Cash ROIC |
(81.17%) | (50.17%) | (61.22%) | (47.86%) | (24.77%) | (7.48%) | (26.28%) | (27.57%) | (41.53%) | (20.01%) |
Accounts Receivable Turnover |
4.81 | 5.73 | 7.63 | 10.55 | 13.64 | 9.69 | 4.55 | 5.75 | 0.99 | 0.00 |
Accounts Payable Turnover |
3.11 | 1.90 | 1.05 | 0.94 | 1.07 | 0.48 | 0.72 | 0.11 | 0.00 | 0.00 |
Inventory Turnover |
2.25 | 1.95 | 1.48 | 1.32 | 1.09 | 0.50 | 0.97 | 0.29 | 0.00 | — |
Average Days of Payables |
103.81 | 184.87 | 341.59 | 557.73 | 390.77 | 769.60 | 521.53 | 3,909.58 | 3,243,390.00 | 0.00 |
Days of Inventory on Hand |
174.13 | 213.31 | 275.53 | 344.97 | 370.08 | 777.05 | 467.84 | 2,250.20 | 276,305.00 | — |
Average Receivables |
140.00 | 97.70 | 56.92 | 34.44 | 25.76 | 27.97 | 22.79 | 8.96 | 2.64 | — |
Average Payables |
35.00 | 40.56 | 42.69 | 30.21 | 15.03 | 12.90 | 12.57 | 10.58 | 7.13 | 4.15 |
Average Inventory |
48.50 | 39.48 | 30.37 | 21.50 | 14.64 | 12.30 | 9.31 | 3.91 | 4.00 | — |
Average Assets |
1,517.50 | 1,497.01 | 1,518.23 | 1,533.92 | 1,640.98 | 1,447.53 | 927.53 | 605.16 | 515.69 | 550.10 |
Average Common Equity |
87.50 | 265.21 | 313.95 | 637.53 | 1,038.47 | 904.07 | 631.34 | 496.18 | 428.71 | 502.53 |
Columns are period end dates